A randomised, placebo-controlled, double-blind, phase I clinical trial to evaluate the safety and immunogenicity of a candidate prophylactic pHIS-HIV-AE DNA prime and rFPV-HIV-AE boost HIV vaccination strategy
Latest Information Update: 18 Sep 2021
At a glance
- Drugs HIV DNA vaccine; HIV vaccine
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- 13 Jun 2012 Biomarkers information updated
- 12 Jun 2012 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
- 12 Jun 2012 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.